کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3970089 | 1256696 | 2015 | 5 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Diagnostic accuracy of hysterosalpingo-foam-sonography to confirm tubal occlusion after Essure® placement as treatment for hydrosalpinges Diagnostic accuracy of hysterosalpingo-foam-sonography to confirm tubal occlusion after Essure® placement as treatment for hydrosalpinges](/preview/png/3970089.png)
• We evaluated the diagnostic accuracy of hysterosalpingo-foam sonography (HyFoSy) to confirm proximal tubal occlusion in subfertile women treated for a hydrosalpinx by an Essure® intratubal device.
• HyFoSy is as able as HSG to confirm proximal tubal occlusion after placement of an Essure® device as treatment for a hydrosalpinx prior to IVF.
• If HyFoSy demonstrates tubal patency, a subsequent HSG needs to be performed to validate this finding.
• HyFoSy does not expose patients to radiation like during HSG.
• HyFoSy is a less painful and a less time-consuming examination compared with HSG.
Consensus globally is that hydrosalpinges need to be treated before IVF owing to their negative influence on outcomes. The current standard treatment is laparoscopic salpingectomy. A potential less invasive treatment is proximal occlusion of a hydrosalpinx by hysteroscopic placement of an Essure® device. Tubal occlusion after Essure® placement needs to be verified by hysterosalpingography (HSG). However, this is a painful examination, that exposes patients to radiation. Hysterosalpingo-foam sonography (HyFoSy) is a less invasive alternative test to confirm proximal tubal occlusion. This prospective diagnostic accuracy study evaluated if HyFoSy is as accurate as HSG to confirm proximal tubal occlusion after placement of an Essure® device as treatment for a hydrosalpinx before IVF. Thirty-eight treated hydrosalpinges in 26 women were evaluated. Proximal occlusion was verified by HyFoSy (index test) and HSG (standard reference). The accuracy of HyFoSy was 97.4% (95% CI 92.3% to 100.0%). Sensitivity and specificity were 97.1% (95% CI.84.6% to 99.5%) and 100.0% (95% CI 40.2% to 100.0%), respectively. After an Essure® device is placed as treatment for a hydrosalpinx before IVF, HyFoSy is as able as HSG to confirm proximal tubal occlusion. If HyFoSy demonstrates tubal patency, a subsequent HSG needs to be carried out to validate this finding.
Journal: Reproductive BioMedicine Online - Volume 30, Issue 4, April 2015, Pages 421–425